Cassava Sciences Board Oversees Enterprise Risk Management
Ticker: FLNA · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, risk-management, cybersecurity
TL;DR
Cassava Sciences' board is on top of risks, including cybersecurity, for FY24.
AI Summary
Cassava Sciences Inc. filed its 2024 10-K on March 3, 2025, detailing its fiscal year ending December 31, 2024. The company's Board of Directors oversees risk management, including identifying, assessing, and managing enterprise-level risks through full board and committee oversight. This process is supported by management reporting designed to provide visibility into critical risks and mitigation strategies, with a specific focus on integrating its cybersecurity risk program.
Why It Matters
This filing outlines how Cassava Sciences' leadership manages potential threats to the company, including a focus on cybersecurity, which is crucial for protecting sensitive data and ensuring operational continuity in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical industry, which inherently carries significant risks related to drug development, regulatory approval, and market competition, in addition to the enterprise-level risks managed by the board.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the reporting period for the 2024 fiscal year.)
Key Players & Entities
- Cassava Sciences Inc. (company) — Filer of the 10-K
- 2024 (date) — Fiscal year end
- March 3, 2025 (date) — Filing date
- Board of Directors (company) — Oversees risk management
FAQ
What is the primary focus of Cassava Sciences' risk management process as overseen by the Board of Directors?
The Board of Directors oversees the identification, assessment, and management of enterprise-level risks, with a specific program designed to integrate and align with cybersecurity risks.
When was Cassava Sciences Inc.'s 2024 10-K filing submitted to the SEC?
The 10-K filing was submitted on March 3, 2025.
What is the fiscal year end for the period covered by this 10-K filing?
The fiscal year end for this filing is December 31, 2024.
How does the Board of Directors administer its risk oversight function?
The Board administers its risk oversight function directly as a whole and through its standing committees, supported by management reporting processes.
What is the SIC code for Cassava Sciences Inc.?
The Standard Industrial Classification (SIC) code for Cassava Sciences Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding CASSAVA SCIENCES INC (FLNA).